Posted by Michael Wonder on 27 Jun 2022
Positive MHRA decision for Briviact
24 June 2022 - MHRA extends UCB’s therapy for the treatment of partial-onset seizures.
UCB has announced that the MHRA has approved a label extension for seizure treatment, Briviact – also known as brivaracetam. The conclusion arrived after pioneering, group-specific data was used during the decision-making process.
